Cataract 4, Multiple Types (CTRCT4) Cell Models for Research

Cataract is the leading cause of blindness worldwide, affecting over 65 million people (WHO, 2020). Congenital cataracts account for about 10% of childhood blindness, with an estimated incidence of 1-6 per 10,000 live births. Cataract 4, Multiple Types (CTRCT4) is a rare autosomal dominant form of congenital cataract, often presenting as lamellar or nuclear opacities. Early onset leads to visual impairment and amblyopia if not surgically treated. Genetic diagnosis is crucial for prognosis and family counseling. The 5-year survival is generally good if treated, but untreated cases have significant morbidity.

CTRCT4 provides a unique opportunity to study lens development and protein aggregation. The disease is caused by mutations in the CRYGD gene, which encodes gamma-D crystallin, a key structural protein in the lens. Research models help elucidate the molecular mechanisms of cataract formation, including protein misfolding and aggregation. Public datasets, such as ClinVar and gnomAD, provide mutation frequencies and pathogenicity data. Open questions include the role of modifier genes and the potential for pharmacological chaperones to prevent aggregation.

Although cataract is not a cancer, the molecular pathways involved in lens development and protein homeostasis are critical. Key pathways include:

• • Protein folding and aggregation: Mutations in CRYGD disrupt the beta-gamma crystallin structure, leading to protein misfolding and aggregation.
• • Apoptosis: Accumulation of misfolded proteins triggers endoplasmic reticulum (ER) stress and unfolded protein response (UPR), leading to lens epithelial cell apoptosis.
• • Oxidative stress: Reactive oxygen species (ROS) can damage crystallins and contribute to aggregation.

These pathways are analogous to those implicated in neurodegenerative diseases, making CTRCT4 a valuable model for protein aggregation disorders.

Data from ClinVar and COSMIC.

Key signaling networks involved in lens development and cataract pathogenesis include:

• • Wnt signaling: Regulates lens epithelial cell proliferation and differentiation.
• • FGF signaling: Essential for lens fiber cell differentiation.
• • TGF-beta signaling: Involved in epithelial-mesenchymal transition (EMT) and fibrosis, contributing to posterior capsule opacification.
• • PI3K/AKT pathway: Regulates cell survival and apoptosis.

In CTRCT4, mutant crystallins can activate ER stress pathways (PERK, IRE1, ATF6) and NF-kB, leading to inflammation and cell death.

Organoids recapitulate lens development and are useful for studying cataract formation in a 3D context.

Animal models for CTRCT4 include:

• • GEMMs: Mice carrying CRYGD mutations (e.g., P23T) exhibit cataracts.
• • Induced models: UV or oxidative stress-induced cataract models in rodents.
• • PDX: Not applicable for cataract, but lens organoids can be transplanted.

These models are valuable for studying disease progression and testing therapies.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific CRYGD mutations (e.g., P23T, R58H) in a wild-type background. These models are essential for studying the direct effects of mutations on protein aggregation and cellular toxicity. Commercially available, sequence-verified knockout and knock-in cell lines accelerate research by providing reproducible and validated models. For example, a CRYGD knockout line can be used to study loss-of-function effects, while a knock-in line with a disease mutation can model the dominant-negative effect. These models are crucial for drug screening and mechanistic studies.

Gene-edited cell lines are used to validate the function of CRYGD and other cataract-associated genes. For example, CRISPR knockout of CRYGD in lens epithelial cells can reveal its role in maintaining lens transparency. Knock-in of disease mutations allows researchers to study the molecular consequences, such as protein aggregation and ER stress. These models are also used in genome-wide screens to identify modifiers of cataract formation.

Isogenic cell lines with and without CRYGD mutations are used in high-throughput screening to identify compounds that prevent protein aggregation or reduce ER stress. These models can also be used to test the efficacy of pharmacological chaperones. Additionally, they can be used to study resistance mechanisms to oxidative stress, which is relevant to age-related cataract.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of cells with CRYGD mutations. These genes may serve as therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers of cataract progression, such as secreted proteins or microRNAs.